口服双膦酸盐治疗成年男性智力障碍相关骨质疏松症。
Oral bisphosphonates for osteoporosis in adult males with intellectual disabilities.
机构信息
Neurodevelopmental Physician Lee Specialty Clinic, Louisville, KY, USA.
University of Louisville School of Medicine Louisville, Louisville, KY, USA.
出版信息
J Appl Res Intellect Disabil. 2021 May;34(3):921-925. doi: 10.1111/jar.12862. Epub 2021 Feb 4.
INTRODUCTION
Oral bisphosphonates are first-line agents for treating osteoporosis in men, but there are no studies regarding efficacy of oral bisphosphonates for treatment of osteoporosis in ambulatory male adults with intellectual disability.
METHODS
Nine adult males with intellectual disability and increased fracture risk had been treated with weekly or monthly oral bisphosphonates, vitamin D and calcium for 1-3 years. Post-treatment bone mineral density (BMD), serum 25(OH)D, parathyroid hormone and C-telopeptide of type I collagen were then determined for the first time.
RESULTS
Weekly or monthly oral bisphosphonates were well tolerated and led to significant increases in BMD in all 9 individuals. Serum 25(OH)D level enhanced the "pecent increase of BMD" that occurred in response to bisphosphonate treatment (p < .05).
CONCLUSIONS
Weekly or monthly oral bisphosphonates are well tolerated by ambulatory adult males with ID and are effective in increasing BMD. Higher serum levels of vitamin D appear to improve the efficacy of bisphosphonates and therefore reduce fracture risk in adult males with intellectual disability.
简介
口服双膦酸盐是男性骨质疏松症的一线治疗药物，但目前尚无研究探讨口服双膦酸盐治疗伴有智力障碍的门诊成年男性骨质疏松症的疗效。
方法
9 名伴有智力障碍和骨折风险增加的成年男性已接受每周或每月口服双膦酸盐、维生素 D 和钙治疗 1-3 年。随后首次测定治疗后的骨矿物质密度（BMD）、血清 25（OH）D、甲状旁腺激素和 I 型胶原 C 端肽。
结果
每周或每月口服双膦酸盐均耐受良好，可使 9 名患者的 BMD 均显著增加。血清 25（OH）D 水平增强了双膦酸盐治疗引起的“BMD 百分比增加”（p < 0.05）。
结论
每周或每月口服双膦酸盐可耐受伴有智力障碍的门诊成年男性，可有效增加 BMD。较高的血清维生素 D 水平似乎可提高双膦酸盐的疗效，从而降低智力障碍成年男性的骨折风险。
Zotero 插件